The Department of Infectious Disease and Global Health (IDGH) has a number of programs that conduct research seeking new therapies for diseases associated with bacterial toxins. This research includes development of general strategies for treatment of toxin-mediated diseases, such as human monoclonal antibodies and novel antitoxin agents, and research on specific bacterial diseases in which toxins are the major virulence factors contributing to the manifestation of the disease. Links to more details on our current research programs can be found below.
Bacterial toxin-mediated diseases:
- Clostridium difficile infection (CDI)
- Diarrheagenic E. coli/HUS
- Human monoclonal antibodies
- Novel antitoxin agents